Quantcast

Baltimore biotech Gliknik, Pfizer sign accord

Gliknik Inc., of Baltimore, a biotech that develops novel molecular treatments for autoimmune/inflammatory diseases and cancer, said it has entered into an exclusive worldwide licensing agreement with drug-making giant Pfizer Inc. for its pharmaceutical candidate, GL-2045, a potential treatment for a variety of autoimmune diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *

*